Abstract
Objective
To investigate the prognostic value of the 6-minute walking distance (6-MWD), transcutaneous saturation (tcSO2) and heart rate (HR) obtained during the 6-minute walk test (6-MWT) in pediatric pulmonary arterial hypertension (PAH).Methods
This was an observational study with forty-seven pediatric PAH patients, aged ≥7 years, and diagnosed and followed at the national referral center for pediatric PAH in the Netherlands. All patients performed a comprehensive 6-minute walk test (6-MWT), which measures 6-MWD and tcSO2 and HR before ("baseline"), during ("exercise") and 5 min after ("recovery") the walk test.Results
The 6-MWD expressed either in meters or in sex- and age-corrected z-scores, was associated with transplant-free survival, independently from sex, age, and the presence of a shunt-defect. Shorter 6-MWD correlated with higher WHO-FC and increased NT-pro-BNP. Absolute tcSO2 at exercise and tcSO2-decrease during 6-MWT were associated with transplant-free survival, independent from 6-MWD. Combining tcSO2-decrease with 6-MWD provided the strongest prognostic model. Patients with 6-MWD>352 m (the median 6-MWD) had a better outcome than those with smaller 6-MWD. A large tcSO2-decrease during 6-MWT (>19% for patients with and >5% for patients without a shunt defect) identified patients with worse transplant-free survival both in patients with a 6-MWD above and below the median 6-MWD.Conclusions
The 6-MWD is an independent predictor of prognosis in pediatric PAH, that reflects disease severity and clinically relevant exercise-tolerance and therefore qualifies as a treatment goal. The magnitude of tcSO2-decrease during 6-MWT, adjusted for the presence of a shunt, indicates an additional risk factor for prognosis in children with PAH.References
Articles referenced by this article (31)
Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies.
Am J Cardiol, (1):117-124 2010
MED: 20609658
Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings.
Am J Cardiol, (9):1332-1338 2010
MED: 21029834
Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management.
Circulation, (1):113-122 2011
MED: 22086881
Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).
Eur Heart J, (20):2493-2537 2009
MED: 19713419
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension.
Eur Respir J, (5):858-863 2005
MED: 16264047
Clinical features of paediatric pulmonary hypertension: a registry study.
Lancet, (9815):537-546 2012
MED: 22240409
Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.
Am J Respir Crit Care Med, (2 Pt 1):487-492 2000
MED: 10673190
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.
J Am Coll Cardiol, (4):780-788 2002
MED: 12204511
Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).
Circulation, (2):164-172 2010
MED: 20585012
Heart rate recovery in pulmonary arterial hypertension: relationship with exercise capacity and prognosis.
Am Heart J, (4):580-588 2012
MED: 22520523
Show 10 more references (10 of 31)
Citations & impact
Impact metrics
Article citations
Pulmonary hypertension.
Nat Rev Dis Primers, 10(1):1, 04 Jan 2024
Cited by: 14 articles | PMID: 38177157
Review
Ventricular global function index is associated with clinical outcomes in pediatric pulmonary hypertension.
J Cardiovasc Magn Reson, 25(1):39, 03 Jul 2023
Cited by: 2 articles | PMID: 37400886 | PMCID: PMC10316558
Cardiac Magnetic Resonance Derived Left Ventricular Eccentricity Index and Right Ventricular Mass Measurements Predict Outcome in Children with Pulmonary Arterial Hypertension.
Children (Basel), 10(4):756, 21 Apr 2023
Cited by: 1 article | PMID: 37190005 | PMCID: PMC10137036
Muscle strength is reduced in children with pulmonary arterial hypertension.
Pulm Circ, 13(2):e12246, 01 Apr 2023
Cited by: 1 article | PMID: 37284521 | PMCID: PMC10241349
Prognostic Value of Transthoracic Echocardiography in Children With Pulmonary Arterial Hypertension.
J Am Heart Assoc, 12(6):e023118, 16 Mar 2023
Cited by: 2 articles | PMID: 36926945 | PMCID: PMC10111552
Go to all (28) article citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Application of a new parameter in the 6-minute walk test for manifold analysis of exercise capacity in patients with COPD.
Int J Chron Obstruct Pulmon Dis, 9:1235-1240, 03 Nov 2014
Cited by: 13 articles | PMID: 25395845 | PMCID: PMC4224096
Diagnostic value of the six-minute walk test (6MWT) in grown-up congenital heart disease (GUCH): Comparison with clinical status and functional exercise capacity.
Int J Cardiol, 203:90-97, 22 Oct 2015
Cited by: 11 articles | PMID: 26498869
Decrease in Cerebral Oxygen Saturation During the 6-Minute Walk Test in Pediatric Pulmonary Arterial Hypertension.
Pediatr Cardiol, 40(7):1494-1502, 31 Jul 2019
Cited by: 0 articles | PMID: 31367954
Treatment goals of pulmonary hypertension.
J Am Coll Cardiol, 62(25 suppl):D73-81, 01 Dec 2013
Cited by: 152 articles | PMID: 24355644
Review